Member Info for Wilson63

Delta plus

https://www.cnbc.com/2021/06/24/delta-plus-covid-variant-heres-what-you-need-to-know.html

Covid op here your oppurtunity find Mr fords credentials, it will demonstrate your willingness to contribute to a board you are invested in, say bt 11 o'clock.

In actual fact the company are extremely busy preparing for the future

Novacyt's CE Mark in vitro diagnostic medical devices (IVDs) are regulated by the 1998 IVD Directive 98/79 EC. To receive CE Mark approval, an IVD must meet the "Essential requirements" of the Directive which, for some products, can be self-certified. A new IVD Directive, IVD-R, comes into force across the UK and Europe on 25 May 2022. IVD-R is a more stringent set of requirements including more detailed verification and validation data and, in most cases, clinical studies to demonstrate conformity with the enhanced Essential requirements reviewed by a notified body to approve the CE Mark. To prepare for the implementation of the new Directive, Novacyt is investing in its regulatory and clinical trial expertise to build on its existing resources, which the Directors believe provides the Company with certain competitive advantages compared to many of its competitors to be ready for this change.

For those that appear to have missed the recent Rns or just want to totally ignore it, here you are spend an hour of your time reading about a real company.

https://www.lse.co.uk/rns/NCYT/full-year-2020-results-and-update-on-strategy-8og71kzsk2gh2do.html

We need all of the above seemingly the travel industry want more

https://www.bbc.co.uk/news/uk-57606348

You couldn't make it up kids eh innovation at its best

https://www.liverpoolecho.co.uk/news/liverpool-news/schools-warning-children-using-fruit-20896618

Tks to Michael burnham

Has changed Balearics etc from 30th June let the pcr's role chart half way down page

https://www.bbc.co.uk/news/uk-57599477

Porky9 that's fantastic that SNPsig can already detect delta plus when most of us on here who have a decent ear to the ground have just heard of it in the last few days.

Now where's that pinata

If we are very near lft whatever side of June/July surely Directors can't/would get slaughtered if they bought just before.

I thought our recent visitor was very wrong but polite I went to uk2days normal stomping ground yesterday and that poster and a few others have to put up with a serious infestation.

Three areas stated in Rns

https://www.cedars-sinai.org/health-library/diseases-and-conditions/c/cmv-and-transplant-patients.html

https://www.nature.com/articles/s41409-019-0548-7

And
https://www.sciencedirect.com/science/article/pii/S2590059520302053

So how on earth can a one legged donkey (a wooden one at that) manage all of this.

. As such, the R&D team has more than doubled in size and now includes the bioinformatics team and a clinical trial function.
As such, the R&D team has more than doubled in size and now includes the bioinformatics team and a clinical trial function.

This clinical trial expertise is a key requirement of the new IVD-R regulation being introduced in May 2022. The team consists of more than 40 qualified people dedicated to designing, running and reporting on clinical trials in the UK, Europe, US and Latin America. During the year, this team completed over a dozen product validations. To date, Novacyt has run six clinical trials in support of its product development and is able to assess new products (internal and external) rapidly and thoroughly through this operation. This, coupled to our bioinformatics and surveillance functionality, will enable the Group to remain at the forefront of new diagnostic innovation as part of our growth plans.

Just go to show it's not just one of these

https://www.amazon.co.uk/Donkey-Pinata/s?k=Donkey+Pinata

that keeps on producing.

Exmex thank you that puts the whole thing in plain language and tells us how important this could be for us I didn't take it in first two reads but it was highlighted by troublesome.

Kaeren from Rns

COVID-19 Plus testing - targeting expansion into closely adjacent areas of COVID-19, and biomarker monitoring to predict COVID-19 progression and to diagnose conditions in affected patients

Following on from butchers bikes post, from the Rns

In October 2020, the Company acquired IT-IS International Limited, a profitable diagnostic instrument development and manufacturing company, for a net cash consideration of £8.7m. IT-IS is the exclusive manufacturer of Novacyt's q16 and q32 rapid PCR instruments. The transaction reinforced our strategy, securing key IP, expanding our core capabilities in instrument manufacturing and strengthening our product offering in mobile PCR devices with an immediate increase in earnings.



IT-IS is an important addition to the business's capability, acquiring a deep knowledge of and expertise in PCR instrumentation to support continued innovation, and we now have a guaranteed supply of q16 and q32 instruments which can easily be scaled depending on demand.

So to reiterate net cost 8.7 mil and easily scaled up also its not even the sale of these machines which is fantastic but the fact our other 550 products can be used on them.

Easychair I think we may hold off but I'm expecting us to buy much cheaper companies which may be harder than you think.
Our recent visitor from sareum proves that great potential products no money but market cap 30 mil behind ours, so finding the appropriate buys must be blooming hard.

Troublesome being a plankti (sounds better than planker) I was dozy before apologies.

Good morning troublesome are you wishing me to drown?

Was just kicking about and found this statement about no share in particular

If you're holding the shares of a company who’s business is growing & improving (and will continue to do so for months / years to come) do not be concerned about the price the market offers for those shares today / tomorrow - unless you want to take advantage of a bargain price.

Credit where it's due Tks to Justin Waite.

Louis _Winthrop I think you said in one sentence what I slavered on about for a paragraph.

It's just f'ing boring isn't it whatever we do it's a but this a but that a but my rear end. We could debate the point that the company should have clarified the dhsc issue but in reality what difference has it made, ah but they will only make 100 mil (min) this year, ah but they've only got this this this this ah but.

I'm going to stick my head in a bucket of sand now to see what the visionary's of the investing world can see that I'm missing.

Was late last night so reposting

https://twitter.com/NovacytGroup/status/1407380082990239755

Jrdc the broker or company today said 100mil for the year pretty much worst case scenario so that's 375k a day worst case scenario not bad and didn't deserve today's price drop.

I'll defer to your politer response kaeren.
Anyway noticed the latest bioinformatics report hasn't been posted so here it is

https://twitter.com/NovacytGroup/status/1407380082990239755

Let's hope this madness ends soon depressing......Scotland result that is we scored a goal so I had a cheer, hey ho.

Novacyt onwards and upwards see you all tomorrow.